In its latest earnings report, Iovance confirmed plans to reduce its workforce by 19% in a bid to save $100 million in yearly costs.

The smaller market now envisioned for vepdegestrant has changed both companies’ stance on their original deal, leading to negotiations that could eith...

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new warnings and restricts vacci...

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts anticipated, leading to a sellof...

The initiative is a response to a Trump administration order to speed the construction of the type of new drug factories many pharmaceutical companies...

The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded to drugs like Keytruda.

Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo dec...

Decades-long research has yielded a strong and growing franchise built around drugs for a genetic form of lung cancer.